BioCentury | Feb 6, 2020
Product Development

Early signs CAR NKs could compete with CAR Ts in heme cancers

Early clinical data from CAR NK cells have started to roll in, and hint the modality could compete with CAR T cells on efficacy. Built into CAR NK cells are the benefits of off-the-shelf manufacturing...
BC Extra | Dec 10, 2019
Clinical News

Investors reward Fate for off-the-shelf NK data at ASH

Fate’s 41% gain following presentations at ASH solidifies its iPS cell-derived NK platform’s status as the company’s center of gravity. The company is advancing a series of increasingly complex off-the-shelf NK cell therapies, with a...
BC Innovations | Dec 6, 2019
Targets & Mechanisms

Bispecifics and allogeneics steal the spotlight from autologous CAR Ts

Standing out at this year's ASH meeting is a pair of growing threats to first-generation CAR T cell therapies: bispecific antibodies and allogeneic cell therapies. Gone are the days when autologous CAR Ts were the...
BC Extra | Sep 13, 2019
Financial News

Sept. 12 Financial Quick Takes: IPOs from 10x, SpringWorks; plus Shanghai Henlius, Fate and more

Big gain for 10x after upsized IPO prices above range  Single-cell analytics company 10x Genomics Inc. (NASDAQ:TXG) gained $13.75 (35%) to $52.75 in its first day of trading after raising $390 million in its IPO....
BioCentury | Sep 4, 2019
Finance

Nkarta’s $114M series B to fund clinical NK cell programs, manufacturing facility

After stretching its $11.5 million series A round to bring its most advanced preclinical NK cell programs within a year of IND submissions while assembling a management team with expertise ranging from discovery to manufacturing,...
BC Extra | Jul 1, 2019
Financial News

Versant, Bayer bet big on iPS cells to tackle price, efficacy of CAR therapies

Looking to tap allogeneic iPS cells to address the shortcomings of CAR cell therapies, Bayer and Versant Ventures launched Century Therapeutics on Monday with $250 million in funding. It’s the second time the partners have...
BC Extra | Jan 17, 2019
Preclinical News

NIH to bring iPS cell therapy into clinic for dry macular degeneration

Researchers at NIH's National Eye Institute (NEI) developed clinical-grade protocols for producing an autologous induced pluripotent stem cell-derived therapy for dry age-related macular degeneration. NEI plans to use the methods, reported in a Science Translational...
BC Week In Review | Dec 7, 2018
Clinical News

Fate to bring iPS cell therapy to clinic

Fate Therapeutics Inc. (NASDAQ:FATE) gained $1.26 to $15.36 on Nov. 30 after announcing that FDA will allow the biotech to move forward with a clinical trial of its allogeneic NK cell therapy FT500, which Fate...
BC Extra | Nov 30, 2018
Clinical News

Fate to bring iPS cell therapy to clinic

Fate Therapeutics Inc. (NASDAQ:FATE) gained $1.26 to $15.36 Friday after announcing that FDA will allow the biotech to move forward with a clinical trial of its allogeneic NK cell therapy FT500, which Fate says would...
BC Innovations | Nov 30, 2018
Targets & Mechanisms

Revving up metabolism at ASH 2018

Cancer metabolism is a prominent theme at this year’s ASH meeting, with researchers broadening the tent from metabolic targets that drive hematologic malignancies to those that intersect with other hot topics, notably immuno-oncology and epigenetics....
Items per page:
1 - 10 of 135
BioCentury | Feb 6, 2020
Product Development

Early signs CAR NKs could compete with CAR Ts in heme cancers

Early clinical data from CAR NK cells have started to roll in, and hint the modality could compete with CAR T cells on efficacy. Built into CAR NK cells are the benefits of off-the-shelf manufacturing...
BC Extra | Dec 10, 2019
Clinical News

Investors reward Fate for off-the-shelf NK data at ASH

Fate’s 41% gain following presentations at ASH solidifies its iPS cell-derived NK platform’s status as the company’s center of gravity. The company is advancing a series of increasingly complex off-the-shelf NK cell therapies, with a...
BC Innovations | Dec 6, 2019
Targets & Mechanisms

Bispecifics and allogeneics steal the spotlight from autologous CAR Ts

Standing out at this year's ASH meeting is a pair of growing threats to first-generation CAR T cell therapies: bispecific antibodies and allogeneic cell therapies. Gone are the days when autologous CAR Ts were the...
BC Extra | Sep 13, 2019
Financial News

Sept. 12 Financial Quick Takes: IPOs from 10x, SpringWorks; plus Shanghai Henlius, Fate and more

Big gain for 10x after upsized IPO prices above range  Single-cell analytics company 10x Genomics Inc. (NASDAQ:TXG) gained $13.75 (35%) to $52.75 in its first day of trading after raising $390 million in its IPO....
BioCentury | Sep 4, 2019
Finance

Nkarta’s $114M series B to fund clinical NK cell programs, manufacturing facility

After stretching its $11.5 million series A round to bring its most advanced preclinical NK cell programs within a year of IND submissions while assembling a management team with expertise ranging from discovery to manufacturing,...
BC Extra | Jul 1, 2019
Financial News

Versant, Bayer bet big on iPS cells to tackle price, efficacy of CAR therapies

Looking to tap allogeneic iPS cells to address the shortcomings of CAR cell therapies, Bayer and Versant Ventures launched Century Therapeutics on Monday with $250 million in funding. It’s the second time the partners have...
BC Extra | Jan 17, 2019
Preclinical News

NIH to bring iPS cell therapy into clinic for dry macular degeneration

Researchers at NIH's National Eye Institute (NEI) developed clinical-grade protocols for producing an autologous induced pluripotent stem cell-derived therapy for dry age-related macular degeneration. NEI plans to use the methods, reported in a Science Translational...
BC Week In Review | Dec 7, 2018
Clinical News

Fate to bring iPS cell therapy to clinic

Fate Therapeutics Inc. (NASDAQ:FATE) gained $1.26 to $15.36 on Nov. 30 after announcing that FDA will allow the biotech to move forward with a clinical trial of its allogeneic NK cell therapy FT500, which Fate...
BC Extra | Nov 30, 2018
Clinical News

Fate to bring iPS cell therapy to clinic

Fate Therapeutics Inc. (NASDAQ:FATE) gained $1.26 to $15.36 Friday after announcing that FDA will allow the biotech to move forward with a clinical trial of its allogeneic NK cell therapy FT500, which Fate says would...
BC Innovations | Nov 30, 2018
Targets & Mechanisms

Revving up metabolism at ASH 2018

Cancer metabolism is a prominent theme at this year’s ASH meeting, with researchers broadening the tent from metabolic targets that drive hematologic malignancies to those that intersect with other hot topics, notably immuno-oncology and epigenetics....
Items per page:
1 - 10 of 135